一例宫颈癌患者使用氨磷汀进行肾保护的合理性分析及文献复习  

Safety and rationality evaluation and review of renal protection treatment with amifostinein in a case of cervical cancer

作　　者：张莲卿 王先利 庞艳玉 法艳梅 孙慧 ZHANG Lian-qing;WANG Xian-li;PANG Yan-yu(Pharmacy Department,the First People’s Hospital of Qujing,Qujing,Yunnan 655000,China;Pharmacy Department,the Affiliated Gynecology Hospital of Fudan University,Shanghai 200011,China)

机构地区：[1]曲靖市第一人民医院药学部,云南曲靖655000 [2]复旦大学附属妇产科医院药剂科,上海200011

出　　处：《中国处方药》2020年第1期50-51,共2页Journal of China Prescription Drug

基　　金：昆明医科大学教研教改课题（2018-JY-Y-102）

摘　　要：目的探讨1例宫颈癌患者化疗治疗中,应用氨磷汀进行肾保护治疗全过程进行安全性及合理性评价。方法临床药师通过查阅文献资料,对1例宫颈癌患者术后化疗联用氨磷汀治疗全过程进行安全性和有效性评价。结果该患者使用氨磷汀存在不足之处。结论对于宫颈癌的患者,目前尚无高质量证据显示氨磷汀预防铂类药物肾毒性有效,宫颈癌化疗前使用氨磷汀仍需进一步研究证明其疗效。Objective To evaluate the safety and rationality of the whole process of renal protection treatment with amifostinein in a case of cervical cancer during chemotherapy.Methods The safety and efficacy of combined treatment with amifostine in one patient with cervical cancer was evaluated by clinical pharmacists through literature review.Results There were some deficiencies in the use of amifostine in this patient.Conclusion For patients with cervical cancer,there is no high quality evidence that amifostine is effective in preventing nephrotoxicity of platinum drugs.Further studies are needed to confirm the efficacy of amifostine in cervical cancer before chemotherapy.

关 键 词：氨磷汀 临床药师 肾毒性 宫颈癌化疗 

分 类 号：R969.3[医药卫生—药理学]